Paediatric critical COVID-19: clinical features and outcomes during five waves.

Introduction

On January 30, 2020, the World Health Organization (WHO) reassessed the potential impact of COVID-19 on global public health and subsequently declared COVID-19 a public health emergency of international concern.¹ This pandemic has caused a considerable number of hospitalizations among adults, especially in intensive care units, with many deaths were deplored, especially among the elderly population.¹ Current research and data have proven that the clinical forms of paediatric cases are most often minor, moderate, or even asymptomatic,² however, the disease can evolve into Acute Respiratory Distress Syndrome (ARDS), multi-organ dysfunction, and result in death in children.³ The first severe paediatric case published in China was of a one-year-old infant.⁴ Tunisian children were spared from severe forms during the first months of the pandemic. After two years of the evolution of the pandemic, publications concerned with severe paediatric forms, involving the vital prognosis, are scarce. The impact of comorbidities on the severity of infection is also controversial.

To our knowledge, this is the first publication concerned with severe and potentially fatal forms in a Tunisian paediatric population.

The objective of our study is to describe the clinical, biological, and therapeutic particularities of severe and critical SARS-CoV-2 infection among paediatric patients admitted in a Tunisian intensive care unit.

Methods

Results

Diagnosis confirmation, laboratory, and radiological findings

The diagnosis was confirmed by RT-PCR for 24 patients (92.3%). The other two cases were confirmed by detection of IgM antibodies in the presence of suggestive symptoms. A rapid antigen detection test was maintained for fifteen children before confirmation by RT-PCR and it was recorded positive in 13 cases (86.6%).

Chest radiography showed bilateral diffuse alveolar-interstitial infiltrate in nine cases (among 12 performed chest radiography).

Ground glass opacities were present in the chest-computed tomography (CT) of 11 patients.

Specialized echocardiography was performed in 11 cases. It showed a large circumferential pericardial effusion of 35 mm with tamponade in one case (Figure 1).

Figure 1. Echocardiography shows a large circumferential pericardial effusion of 35 mm with a tamponade.

Additional laboratory and radiological findings are shown in Table 3.

Table 3. Diagnosis confirmation, laboratory and radiological findings.

Variables	Value
SARS-CoV-2 infection
SARS-CoV-2 rapid test, n=26	13
Nasopharyngeal RT – PCR, n=26	24
IgM against SARS-CoV-2, n=2	2
Laboratory findings
Hyperleukocytosis, n=26	17
lymphocyte predominance, n=26	12
Neutropenia, n=26	1
Lymphopenia, n=26	2
Anaemia, n=26	7
CRP (C-reactive protein)>20 mg/l, n=26	8
Procalcitonin (PCT) > 0.5 g/l, n=5	3
Fibrinogen > 2.5 g/l, n=7	5
Troponine>14 ng/L, n=18	6
Pro-BNP > 400 ng/L, n=13	9
Alanine aminotransferase and or Aspartate aminotransferase > 40 UI/L, n=26	11
Ferritinemia> 500 ng/ml, n=8	4
D-dimer > 500 μg/l, n=12	10
Chest radiography result n=12
Bilateral diffuse alveolar interstitial infiltrate	9
Chest distension	3
CT of the thorax result, n=16
Ground glass opacities	11
Crazy paving	1
Aspect of non-COVID-19 pneumonia	2
Others: collapsed pneumothorax	2
Echocardiography result, n=11
Congenital heart disease	3
Pericarditis	2
Tamponnade	1
Myocarditis	1
Left ventricular ejection fraction<50%	4

Discussion

In this study, we report the characteristics and clinical course of 26 severe and critically ill infants and children with COVID-19 hospitalized during the first two years of the pandemic at paediatric department of Farhat Hached Sousse Tunisia.

The first paediatric publications concluded that the disease was mild.² Publications of severe and critical paediatric forms, involving the vital prognosis, are still rare. Thereupon, several studies were published in the west demonstrating the characteristics of children infected with COVID-19 and requiring intensive care.^6–8 In our series, the percentage of children admitted to intensive care was 20.8% of the total number of children hospitalized for COVID-19. This percentage was higher than the rate reported in a series published earlier in China, which included 2,135 children. In the literature, the rate of admission to the PICU varies from 5.9 to 39% among hospitalized children.^2,3,8

According to our findings, Chinese publications settled that the majority of serious and critical cases were seen in children under the age of one year.²

This has important implications and requires amplified monitoring in children less than one year of age. However, we noted that the age group of one to five years was the less affected. This result was observed in North America.⁶ Consistent with other series, our study found that school-aged children and adolescents exceed 30% of patients hospitalized for COVID-19 in PICU.^6,8

We noted in our series the predominance of the male gender. One key discovery in understanding the mechanism of SARS-CoV-2 infection involves the role of the transmembrane serine protease 2 (TMPRSS2), MPRSS2 is a critical factor enabling cellular infection by SARS-CoV-2. Some authors put forward the hypothesis that the modulation of its expression by sex steroids could contribute to the male predominance of severe infection.⁹ A preponderance of the male gender was noted in the paediatric series of Chao et al. (67.4%)⁷ and Shekermedian (80%)⁶ but Tsabouri et al., concluded that male sex is not an independent risk factor for severity in children.¹⁰

Moreover, multicentre studies have described high rates of comorbidities in children hospitalized in PICU with COVID-19.¹¹ Congenital heart disease was communal in our series, followed by neurological and endocrine aetiologies. These comorbidities were predominant in severe cases in the series of the literature.^12,13 The hypotheses proposed to explain the severity of COVID-19 in children with congenital heart disease by: the destructive effect of COVID-19 on the heart,¹³ the poor prognosis of influenza and other viral respiratory diseases in these children,¹⁴ and the fact that many of these patients may have concomitant abnormalities in other organs, such as the lungs and kidneys.¹⁵ On the other hand, the severity of these forms in children who have neurologic disorders could be attributed to the decrease in muscle tone and strength, mobility alteration or structural conditions.¹⁶ Early studies have shown that individuals at high risk of metabolic dysfunction appeared at higher risk for complications, but the relationship between diabetes and COVID-19 is still not well understood. Instead, a new hypothesis has emerged, which suggests a bidirectional relationship between diabetes and COVID-19.¹⁷

As was expected, in our study, and in published studies, the most common presenting symptoms were fever followed by lower respiratory tract symptoms in more than 60% of children.⁸

Likewise, COVID-19 can progress to ARDS and multi-organ dysfunction. To emphasize, respiratory and cardiovascular involvement were predominant in our series. In our series, we noted four cases (15.3%) of ARDS. This was similar to that observed in paediatric COVID-19 patients admitted to intensive care units in Brazil (13%).⁸ In our series, only one child did not need MV and was supported with NIV and HFNC. In general, SARS-CoV-2 ARDS is described as an atypical form of ARDS. The main characteristic is the dissociation between relatively well-preserved pulmonary compliance and the severity of hypoxemia.¹⁸ In our series, we found that respiratory and hemodynamic distress were the main indications for ICU hospitalization. Fisler et al., have found that hypoxia, hemodynamic instability, pneumonia, or ARDS were the most frequent indications for PICU admission.³

Paying attention to the two cardiovascular manifestations of the patients of our series: Tamponnade and myocarditis. Pericarditis complicated by tamponade has been described even in children with COVID-19.¹⁹ The pathogenesis of tamponade secondary to COVID-19 is still unknown. Two mechanisms could be incriminated. The first one: cardiac affinity of the virus which could be explained by the direct binding of the S protein of SARS-CoV-2 to the human angiotensin converting enzyme 2 present in the human heart, allowing a cellular infection.²⁰ The second mechanism: the cytokine storm triggered by an imbalanced response of type 1 and type 2 helper T cells.²¹

Myocarditis is a cardiac manifestation that was also observed in our study. The mechanism of cardiac injury is not well defined, but it might be caused by direct myocardial infection, hypoxemia, and indirect injury due to systemic inflammatory response. Myocardial necrosis and endothelial involvement were found in biopsies performed in post-mortem. Given that, pathological processes included direct myocardial injury through virus binding to ACE2, systemic inflammation, and altered myocardial demand-supply ratio.²²

Since our series is unusual by the diversity of manifestations extrapulmonary, we have identified neurological symptoms, which ranged from non-specific or specific mild symptoms such as altered state of consciousness and seizures. For neurological distress, in the series of Qiu et al., refractory seizures were the main causes of admission to PICU.²³ Two infants had encephalitis. An autopsy report has documented the presence of SARS-CoV-2 in the brain tissue of a COVID-19 patient. Thus, there is no definitive conclusion on the mechanisms of SARS-CoV-2 neuro-invasion. These proposed mechanisms include direct viral invasion, systemic blood circulation, or distribution of infected immune cells.²⁴

One patient had a Meningococcal meningitis and COVID-19 co-infection.

Bacterial coinfection is more common in paediatrics, particularly for pneumococcus and meningococcus. The frequent carriage of the bacteria explains coinfection with meningococci at this age. However, the mechanism is not yet known. Bacterial co-infection with meningococcus was also reported in a 22-year-old woman.²⁵

In our series, two children were hospitalized with severe DKA. A descriptive study carried out in Germany resolved that there was a significant increase in the frequency of diabetic decompensation in the area of COVID-19 in children newly diagnosed with type 1 diabetes.²⁶ SARS-CoV-2 can trigger severe DKA for people with new-onset diabetes. However, at present, there is no perceptible evidence that SARS-CoV-2 induces type 1 diabetes.²⁷

Management is essentially symptomatic. With the acquisition of experience in the management of COVID -19 patients, clinicians realized that the mortality on invasive ventilation was high and that when HFNC is used with precautions, it avoids intubation.²⁸ Until now, the use of ONHD in case of ARDS complicating SARS-CoV-2 infection in children is exceptional. In a study carried out in the United States of America, seven children with ARDS were initially treated by HFNC, four had subsequently required mechanical ventilation.⁷ HFNC could have a central role in improving the disease. We need more data and guidelines. Patients treated with HFNC should be closely monitored to detect the need for therapeutic escalation and mechanical ventilation. Patients in our study did not receive Remdesivir or Tocilucimab. Remdesivir was not available in Tunisia and Tociluzimab did not have marketing authorization in paediatrics. We tried exogenous surfactant treatment for our 1-month-old patient with ARDS. In the literature, surfactant was effective in the treatment of ARDS in combination with other therapeutic measures.^29,30

Mortality was marked high in our series (23%)compared with the initial paediatric reports.^2,6–8

Conclusion

Paediatric patients represent a small percentage of all severe and critical SARS-CoV-2cases in the general population. Nevertheless, paediatricians must be vigilant. Our study highlighted the large spectrum of vital clinical presentations as well as the significant occurrence of potentially fatal paediatric cases.

Careful monitoring and early intervention are necessary for an infant less than one year of age and in the presence of comorbidities. We hope that this series will help manage other similar patients with the same conditions. Prevention measures are also necessary to prevent the spread of COVID-19, with the need to protect children who are vulnerable and have comorbidities.